The initial search strategy identified 443 unique studies; screening against inclusion or exclusion criteria yielded 55 randomized controlled trials comparing a-blocker medical expulsive therapy for passage of uncomplicated ureteric stones less than 10 mm versus either a placebo (14 studies) or expectant management (41 studies) control. Tamsulosin was the primary a-blocker used (40 of 55 studies), at various dosages (0.2 to 0.4 mg) and for various durations (7 to 30 days); however, the results did not differ among a-blockers.
Results
The initial search strategy identified 443 unique studies; screening against inclusion or exclusion criteria yielded 55 randomized controlled trials comparing a-blocker medical expulsive therapy for passage of uncomplicated ureteric stones less than 10 mm versus either a placebo (14 studies) or expectant management (41 studies) control. Tamsulosin was the primary a-blocker used (40 of 55 studies), at various dosages (0.2 to 0.4 mg) and for various durations (7 to 30 days); however, the results did not differ among a-blockers.
Patients treated with a-blockers had fewer days until stone passage than controls (8.8 versus 13.3 according to moderate-quality evidence) and 0.74 fewer pain episodes (95% CI 0.21 to 1.28) compared with controls, although quality of evidence was low. Subgroup analysis stratified by stone location in the ureter showed similar benefits for a-blockers in promoting the passage of upper and middle stones (RR 1.48; 95% CI 1.05 to 2.10) and lower ureter stones (RR 1.49; 95% CI 1.38 to 1.63). Overall, a-blockers were not beneficial in the passage of small
Comparison of a-blocker therapy versus control* for ureteric stones. 
Commentary
Emergency department visits for ureteric stones are common, with the majority treated on an outpatient basis. 3 The American Urologic Association and European Association of Urology recommend treating ureteric stones less than or equal to 10 mm with a-blocker medical expulsive therapy, according to randomized controlled trials showing superiority over placebo or expectant management in promoting stone passage. 4, 5 These randomized controlled trials have been criticized as being small and of low quality, so in 2015 Pickard et al 6 
benefit according to stone location, and these results have been found in other meta-analyses. 8 Several limitations apply to these results and are important for the emergency physician to consider. First, although some studies used different cutoffs for the size of small stones, "small" ranging from 5 to 8 mm, the lack of benefit for such stones seems likely to have been driven primarily by 2 large, high-quality, randomized controlled trials using the 5-mm cutoff. Moreover, the 3 studies in the small stone subgroup with larger cutoffs than 5 mm either suggested a-blockers as beneficial versus control (2 studies) or had such a high control group rate of stone passage that a-blockers likely were not beneficial regardless of stone size (one study). This context may therefore support the study authors' assessment that 5 mm is the important cutoff for patient selection, although future confirmatory work using a single 5-mm cutoff would likely be useful.
Another potential limitation is the low quality of evidence in the analysis of severe adverse events that found no difference from controls. A 0.4-mg dose of tamsulosin has fewer vasoactive effects than many a-blockers and a reported 0.4% risk of hypotension requiring hospitalization in adults aged 40 to 85 years, but this rate is highest in the first few weeks of therapy. a-Blocker medical expulsive therapy is likely beneficial for 5-to 10-mm uncomplicated ureteric stones, but much less likely to be useful for stones less than 5 mm. This approach requires imaging able to measure stone size (eg, noncontrast computed tomography), so radiation risk and imaging costs should be weighed against potential benefits. Risk factors for hypotension (patient receiving antihypertensive medications or having severe cardiac or renal disease, arrhythmias, syncopal history, etc) should also be considered in risk-benefit assessments and discussions with patients, given the low quality of evidence in the analysis for serious adverse events. 
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